RGNT.US Regentis Biomaterials Ltd.

Healthcare Health Care Equipment & Supplies USA Stocks
1.19 USD
Close of Nov 17, 2026
1.14 9.40
Market cap
USD 8.36M
P/E
-
P/B
1.12x
ROE
-287.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is RGNT.US undervalued?

Graham number

The Graham number of Regentis Biomaterials Ltd. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Regentis Biomaterials Ltd. fundamental analysis

No fundamental analysis for Regentis Biomaterials Ltd. yet.

Regentis Biomaterials Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Regentis Biomaterials Ltd.

Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorpo…

Full company profile